- Home
- DXCM
DXCM
DexCom Inc.
as 12-18-2024 1:35pm EST
Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 28.0B | IPO Year: | 2005 |
| Target Price: | $98.00 | AVG Volume (30 days): | 3.2M |
| Analyst Decision: | Buy | Number of Analysts: | 17 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.67 | EPS Growth: | 83.21 |
| 52 Week Low/High: | $62.34 - $142.00 | Next Earning Date: | 02-06-2025 |
| Revenue: | $3,954,000,000 | Revenue Growth: | 16.19% |
| Revenue Growth (this year): | 13.1% | Revenue Growth (next year): | 14.79% |
Stock Insider Trading Activity of DexCom Inc. (DXCM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heller Bridgette P | DXCM | Director | Dec 16 '24 | Sell | $76.87 | 1,000 | $76,870.00 | 23,349 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Dec 16 '24 | Sell | $76.87 | 744 | $57,191.28 | 80,030 | |
| Leach Jacob Steven | DXCM | EVP, Chief Operating Officer | Dec 16 '24 | Sell | $76.87 | 744 | $57,191.28 | 264,171 | |
| Stern Sadie | DXCM | EVP, Chief HR Officer | Dec 16 '24 | Sell | $76.87 | 424 | $32,592.88 | 70,768 | |
| Stern Sadie | DXCM | EVP, Chief HR Officer | Nov 20 '24 | Sell | $74.73 | 4,259 | $318,275.07 | 70,768 | |
| Sylvain Jereme M | DXCM | EVP, Chief Financal Officer | Nov 15 '24 | Sell | $75.51 | 3,500 | $264,285.00 | 80,030 |
Latest DexCom Inc. News
DXCM Breaking Stock News: Dive into DXCM Ticker-Specific Updates for Smart Investing
Insider Monkey
7 hours ago
AI-Driven Glucose Biosensing: Dexcom’s (DXCM) Path To A Comeback
Business Wire
a day ago
Dexcom Launches the First Generative AI Platform in Glucose Biosensing
Business Wire
a day ago
Alberta Government Lifts Age Restrictions on Continuous Glucose Monitors (CGM) and Eligible Albertans With Type 1 or Type 2 Diabetes Can Now Access Dexcom G7 CGM
Insider Monkey
a day ago
Is Dexcom, Inc. (DXCM) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Zacks
5 days ago
TNDM Stock to Gain From t:slim X2 With Dexcom G7 Launch in Canada
Zacks
5 days ago
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Simply Wall St.
5 days ago
Why DexCom, Inc. (NASDAQ:DXCM) Looks Like A Quality Company
MT Newswires
6 days ago
Nephron Research Adjusts Price Target on DexCom to $125 From $145
Compare DXCM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXCM DexCom Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.